Nikolas Desilet

Patient characteristics and long–term outcomes beyond the first 6 months after a diagnosis of cancer-associated venous thromboembolism

Robert A. Schmidt, Alaa Al Zaki, Nikolas Desilet, Elena Szefer et autres

ca (code pays fourni par la source)

Patient characteristics and long-term outcomes beyond the first 6 months after a diagnosis of cancer-associated thrombosis.

Robert A. Schmidt, Alaa Alzaki, Nikolas Desilet, Namali Ratnaweera et autres

10057 Background: Cancer associated thrombosis (CAT) is a common complication of malignancies. However, little is known about the clinical course of CAT beyond the initial treatment period of 3 to 6 months. This information is important for clinicians and patients to inform …

ca (code pays fourni par la source)

A Novel Case of Direct Antiglobulin Test-Negative Intravascular Hemolysis in a Patient with Smoldering Myeloma

Selina Dobing, Nikolas Desilet, Irwindeep Sandhu, Lauren Bolster

Abstract Objectives: 1. Describe a case of severe DAT-negative intravascular hemolysis in plasma cell dyscrasia. 2. Discuss a potential novel mechanism of light-chain mediated hemolysis. A 34-year old woman was admitted to hospital with fatigue and severe iron deficiency anemia (hemoglobin 47 …

ca (code pays fourni par la source)

p53-based Anti-cancer Therapies: an Empty Promise?

Nikolas Desilet, Francis Y.M. Choy

Since its discovery in 1979, p53 has become the focus of intensive cancer-based research in laboratories around the world. The p53 protein mediates critical cellular functions including the response to genotoxic stress, differentiation, senescence, and apoptosis, and has been shown to be …

ca (code pays fourni par la source)